Clinical Trials Directory

Trials / Unknown

UnknownNCT00022958

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
Sponsor
Corixa Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131 Anti-B1 Antibody.

Conditions

Interventions

TypeNameDescription
DRUGIodine-131 Anti-B1 Antibody

Timeline

Start date
1998-09-01
First posted
2001-08-20
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00022958. Inclusion in this directory is not an endorsement.